Marty Makary: “ADCOMs are bureaucratic, long, often conflicted and very…”

“Hi, Luke Zarzecki with Inside Health Policy going off of that question, why did FDA choose to have an expert panel instead of of an ADCOM meeting, which is usually the Because ADCOMs are bureaucratic, long, often conflicted and very expensive. So we can have an active, robust discussion as a group of medical experts spontaneously. And so we're doing more of that. We're doing both advisory committees following the long FACA process of the government.” (41:12–41:17)

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.